Welcome to our dedicated page for Anika Therapeutics SEC filings (Ticker: ANIK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Anika Therapeutics, Inc. (NASDAQ: ANIK) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Anika uses these filings to report its financial results, clinical and regulatory milestones, governance decisions, and equity compensation arrangements as it advances osteoarthritis pain management and regenerative orthopedic solutions based on hyaluronic acid and implant technologies.
Investors can review Form 8-K current reports in which Anika furnishes press releases on quarterly financial results, such as those for the second and third quarters of 2025, and discusses non-GAAP measures like Adjusted EBITDA and adjusted net income from continuing operations. Other 8-K filings describe material events including the filing of the third and final Premarket Approval (PMA) module for the Hyalofast cartilage repair scaffold, topline results from the U.S. pivotal FastTRACK Phase III study, and amendments to the company’s 2017 Omnibus Incentive Plan approved by stockholders.
Through its proxy-related disclosures and meeting results, Anika reports on governance and compensation matters, including director elections, advisory votes on executive compensation, and increases to share reserves under its omnibus incentive plan. Additional filings document inducement equity grants made under a separate inducement plan in accordance with Nasdaq Listing Rule 5635(c)(4), providing detail on stock option terms and vesting conditions for newly hired employees.
On Stock Titan, these filings are complemented by AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the implications of earnings releases, clinical and regulatory updates, plan amendments, and other material events. Users can track new 8-Ks and other SEC forms as they are posted to EDGAR, and use the summaries to focus on the sections most relevant to Anika’s OA pain management and regenerative solutions strategy, capital structure, and corporate governance.
On 30 Jul 2025, Anika Therapeutics (ANIK) filed a Form 8-K (Item 7.01) to furnish a press release (Exhibit 99.1) announcing top-line results from its U.S. pivotal FastTRACK Phase III study of the Hyalofast cartilage-repair scaffold and providing a program update. No financial figures, efficacy data, or regulatory timelines are included in the filing itself; those details reside in the furnished press release, which is not reproduced here. The information is deemed “furnished,” not “filed,” so it is excluded from Exchange Act liability and will not be automatically incorporated into future SEC filings. Apart from the exhibit list, the 8-K contains no additional disclosures under Items 1–6, and there are no financial statements attached.
On 24 June 2025, Anika Therapeutics (ANIK) filed a Form 4 reporting that director Susan L. N. Vogt was granted 14,164 restricted stock units (RSUs) on 20 June 2025. Transaction code "A" confirms the award was a non-cash grant priced at $0.
Each RSU entitles the holder to one common share and will vest in full on the earlier of the 2026 annual shareholder meeting or 20 June 2026. Following the grant, Vogt's beneficial ownership increased to 50,213 common shares, a notable rise from her prior level.
No derivative securities, sales, or additional acquisitions are disclosed. The filing represents routine director compensation and is unlikely to materially affect Anika Therapeutics' financial condition or share-count, but it strengthens insider alignment with shareholder interests.
Anika Therapeutics (NASDAQ:ANIK) filed a Form 4 reporting that director Stephen Richard received 14,164 restricted stock units (RSUs) on 06/20/2025 at a cost basis of $0. The RSUs vest in full on the earlier of the 2026 annual shareholder meeting or 06/20/2026. After the grant, Richard’s direct beneficial ownership increased to 47,871 common shares.
The filing reflects a routine board compensation award; no open-market purchases or sales were disclosed.
Director equity grant highlighted in Form 4 filing
On 20 June 2025, Anika Therapeutics (ticker: ANIK) director Glenn R. Larsen received an award of 14,164 restricted stock units (RSUs) at an exercise price of $0. Each RSU represents the right to one share of common stock. The units vest in full on the earlier of the 2026 annual shareholder meeting or 20 June 2026.
After the grant, Larsen’s direct beneficial ownership rises to 50,258 common shares. No sales, option exercises or other derivative transactions were reported. The filing reflects routine director compensation rather than an open-market purchase, therefore cash was not exchanged and there is no immediate impact on the company’s outstanding share count or cash position.
While the additional ownership marginally strengthens management–shareholder alignment, the transaction is typical for board-level remuneration and is not by itself a material catalyst for the stock.
Anika Therapeutics (ANIK) – Form 4 insider filing: Director William R. Jellison reported the grant of 14,164 restricted stock units (RSUs) on 20 June 2025. Each RSU converts to one common share upon vesting, which will occur in full at the earlier of the company’s 2026 annual meeting or 20 June 2026. Following the award, Jellison’s direct ownership rises to 20,403 common shares; he also holds 2,700 shares indirectly through a revocable trust. No shares were sold or disposed of, and the grant was made at $0 cost, reflecting a routine, equity-based director compensation transaction.
Anika Therapeutics, Inc. (ANIK) filed a Form 4 on 24 June 2025 detailing an insider equity award to director John B. Henneman III. On 20 June 2025 Mr. Henneman received 14,164 restricted stock units (RSUs) of common stock at a stated price of $0. Each RSU represents the contingent right to receive one ANIK share.
The RSUs vest in full on the earlier of the company’s 2026 annual shareholder meeting or 20 June 2026, aligning the award’s time horizon with shareholder interests over the next 12 months. Following the grant, Mr. Henneman’s total directly held beneficial ownership rises to 49,871 common shares. No derivative securities were exercised, sold, or otherwise disposed of in this filing, and no cash changed hands; the transaction is classified under code “A” (award) under SEC rules.
This appears to be a routine component of director compensation rather than an open-market purchase, yet it still modestly increases insider exposure to the stock. No other material transactions, earnings data, or financial tables were included in the filing.
Anika Therapeutics, Inc. (ANIK) Form 4 filing: Director Gary P. Fischetti reported the award of 14,164 restricted stock units (RSUs) on 20 June 2025. Each RSU converts into one common share at no cost to the director and will vest in full on the earlier of the company’s 2026 annual shareholder meeting or 20 June 2026. Following the grant, Fischetti’s total beneficial ownership increases to 41,613 common shares, held directly. No open-market purchases or sales were reported, and no derivative securities were exercised or disposed of.
Form 4 snapshot: On 06/20/2025, Anika Therapeutics, Inc. (ANIK) director Sheryl L. Conley received an equity grant of 14,164 restricted stock units (RSUs) at no cost. The award lifts her beneficial ownership to 42,568 common shares following the transaction.
The RSUs will vest in full on the earlier of the 2026 annual shareholder meeting or June 20, 2026, providing a one-year vesting horizon. Each RSU converts into one share of ANIK common stock upon vesting, subject to continued service. No derivative securities or open-market purchases/sales were reported, and no 10b5-1 trading plan was indicated.
This filing reflects routine director compensation rather than a discretionary purchase. The share amount is modest relative to ANIK’s 14 million-plus outstanding shares and therefore is unlikely to materially affect the company’s capital structure or near-term valuation. Nevertheless, it marginally strengthens director-level alignment with shareholder interests by increasing Conley’s equity stake.
Insider transaction overview – Anika Therapeutics, Inc. (ANIK)
On 20 June 2025, director Joseph H. Capper filed a Form 4 disclosing the award of 14,164 restricted stock units (RSUs) under transaction code “A” (award/grant). The grant was made at $0 cost; no open-market cash purchase occurred.
After the award, Capper’s total beneficial ownership rose to 20,403 common shares. The RSUs convert to common stock on a 1-for-1 basis and vest in full on the earlier of the 2026 annual shareholder meeting or 20 June 2026, thereby tying compensation to medium-term company performance.
No derivative positions, sales, or additional acquisitions were reported, and the filing contains no financial performance data. The transaction appears to be a routine board-related equity grant that modestly strengthens alignment between the director and shareholders without signaling market sentiment through cash purchases.
Anika Therapeutics held its Annual Meeting on June 20, 2025, with 86.13% shareholder participation (12.35M shares represented). Key outcomes include:
- Board Elections: Three Class II directors elected until 2028 - Cheryl Blanchard, Joseph Capper, and Glenn Larsen, with Capper receiving strongest support (10.5M votes)
- 2017 Omnibus Incentive Plan Amendment: Shareholders approved increasing reserved shares by 475,000 to total 5.76M shares. All shares may be granted as incentive stock options under IRC Section 422
- Other Approvals: Shareholders ratified Deloitte & Touche as independent auditor (12.07M votes in favor) and approved executive compensation in advisory vote (8.37M votes in favor)
The meeting demonstrated strong shareholder engagement, though some proposals like executive compensation and incentive plan amendment faced notable opposition with over 2.5M votes against each.